• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Antimicrob Agents . In silico Study of Azithromycin, Chloroquine and Hydroxychloroquine and their Potential Mechanisms of Action against SARS

tetano

Editor, Senior Moderator
Int J Antimicrob Agents


. 2020 Jul 29;106119.
doi: 10.1016/j.ijantimicag.2020.106119. Online ahead of print.
In silico Study of Azithromycin, Chloroquine and Hydroxychloroquine and their Potential Mechanisms of Action against SARS-CoV-2 Infection


Helyson Lucas Bezerra Braz[SUP] 1 [/SUP], Jo?o Alison de Moraes Silveira[SUP] 2 [/SUP], Aline Diogo Marinho[SUP] 2 [/SUP], Maria Elisabete Amaral de Moraes[SUP] 2 [/SUP], Manoel Odorico de Moraes Filho[SUP] 2 [/SUP], Helena Serra Azul Monteiro[SUP] 2 [/SUP], Roberta Jeane Bezerra Jorge[SUP] 3 [/SUP]



Affiliations

Abstract

The coronavirus disease 19 (COVID-19) is a highly transmissible viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical trials have reported an improved outcome resulting from effective reduction or absence of viral load when patients were treated with chloroquine or hydroxychloroquine. In addition, these drugs had their effects improved by simultaneous azithromycin administration. The Receptor-Binding Domain of SARS-CoV Spike Protein (RBD of S Protein) binds to the cell surface angiotensin-converting enzyme 2 (ACE2) receptors allowing viral entry and replication into the host cells. The viral Main Protease (Mpro) and the Cathepsin L (CTSL) are among the proteolytic systems involved in S Protein activation by SARS-CoV-2. Hence, molecular docking studies were performed to test the binding performance of these three drugs against four targets. Our finding showed azithromycin affinity scores (∆G) with strong interactions with ACE2, CTSL, Mpro and RBD. Chloroquine affinity scores showed 3 low energy results (less negative) with ACE2, CTSL and RBD; and a firm bond score with Mpro. With hydroxychloroquine, two results (ACE2 and Mpro) were firmly bound to the receptors; however, CTSL and RBD showed low interaction energies. The differences in better interactions and affinity between hydroxychloroquine and chloroquine with ACE2 and Mpro were probably due to structural differences between the drugs. Azithromycin, on other hand, not only showed more negative (better) values in affinity, but also in the number of interactions in all targets. Nevertheless, further studies are needed to investigate the antiviral properties of these drugs against SARS-CoV-2.

Keywords: Azithromycin; COVID-19; Chloroquine; Coronavirus; Hydroxychloroquine; Molecular
 
Back
Top Bottom